Benefits of Tranexamic Acid in Total Knee Arthroplasty: A Classification and Regression Tree Analysis in Function of Instrumentation, BMI, and Gender

Abstract

Tranexamic acid (TXA) is an antifibrinolytic drug that reduces blood loss in patients that undergo Total knee arthroplasty (TKA). Few studies compare its effect on conventional instrumentation (CI) versus patient-specific instrumentation (PSI). The main objective of this study was to understand analytically how TXA usage in both instrumentations influenced blood loss in TKA differently and see if the differences seen could be explained by the patient's body mass index (BMI) and gender. This nonrandomized retrospective study sample consisted of 688 TKA procedures performed on patients who had symptomatic arthrosis resistant to conservative treatment. Descriptive analysis was used to evaluate blood loss using hemoglobin (Hb) mean values and mean variation (%). The Classification and Regression Tree (CRT) method was applied to understand how the independent variables affected the dependent variable. Comparing patients submitted to the same instrumentation, where some received TXA and others did not, patients that received TXA had lower blood loss. Comparing patients who underwent TKA with different instrumentations and without the use of TXA, it was found that patients who underwent TKA with PSI had lower blood loss than those who underwent TKA with CI. However, when these same instruments were compared again, but associated with the use of TXA, the opposite was true with patients undergoing TKA with PSI showing greater blood loss than patients undergoing TKA with CI. TXA usage in TKA is significantly beneficial in minimizing blood loss and regardless of instrumentation. When using TXA, the lowest blood loss was obtained in patients with higher BMI and submitted to TKA with CI. This is most likely explained by the synergistic antifibrotic effect of TXA with adipokines, such as plasminogen activator inhibitor-1 (PAI-1), found in the femoral bone marrow which is perforated using CI. If, however, TXA wasn't used, the lowest blood loss was obtained in patients submitted to TKA with PSI.

Keywords

total knee replacement - tranexamic acid - instrumentation - surgical blood loss - plasminogen activator inhibitors

Publikationsverlauf

Eingereicht: 30. Dezember 2020

Angenommen: 01. Mai 2021

Artikel online veröffentlicht:
05. Juli 2021

• References

• 1 Vide J, Freitas TP, Ramos A, Cruz H, Sousa JP. Patient-specific instrumentation in total knee arthroplasty: simpler, faster and more accurate than standard instrumentation-a randomized controlled trial. Knee Surg Sports Traumatol Arthrosc 2017; 25 (08) 2616-2621
• 2 Rodrigues AST, Gutierres MAP. Patient-specific instrumentation in total knee arthroplasty. Should we adopt it?. Rev Bras Ortop 2016; 52 (03) 242-250
• 3 Daniilidis K, Tibesku CO. Frontal plane alignment after total knee arthroplasty using patient-specific instruments. Int Orthop 2013; 37 (01) 45-50
• 4 Daniilidis K, Tibesku CO. A comparison of conventional and patient-specific instruments in total knee arthroplasty. Int Orthop 2014; 38 (03) 503-508
• 5 Predescu V, Prescura C, Olaru R, Savin L, Botez P, Deleanu B. Patient specific instrumentation versus conventional knee arthroplasty: comparative study. Int Orthop 2017; 41 (07) 1361-1367
• 6 White IV CC, Eichinger JK, Friedman RJ. Minimizing blood loss and transfusions in total knee arthroplasty. J Knee Surg 2018; 31 (07) 594-599
• 7 Sun ML, Zhang Y, Peng Y, Fu DJ, Fan HQ, He R. Accuracy of a novel 3d-printed patient-specific intramedullary guide to control femoral component rotation in total knee arthroplasty. Orthop Surg 2020; 12 (02) 429-441
• 8 Turgeon TR, Cameron B, Burnell CD, Hedden DR, Bohm ER. A double-blind randomized controlled trial of total knee replacement using patient-specific cutting block instrumentation versus standard instrumentation. Can J Surg 2019; 62 (06) 460-467
• 9 Pathan S, Cruz JE, Curtin P. Comparison of the effects of intravenous and oral tranexamic acid on perioperative hemoglobin levels during total knee arthroplasty. Ann Pharmacother 2020; 54 (02) 138-143
• 10 Kizaki K, Shanmugaraj A, Yamashita F. et al. Total knee arthroplasty using patient-specific instrumentation for osteoarthritis of the knee: a meta-analysis. BMC Musculoskelet Disord 2019; 20 (01) 561
• 11 Stolarczyk A, Nagraba L, Mitek T, Stolarczyk M, Deszczyński JM, Jakucinski M. Does patient-specific instrumentation improve femoral and tibial component alignment in total knee arthroplasty? A prospective randomized study. Adv Exp Med Biol 2018; 1096: 11-17
• 12 León-Muñoz VJ, Martínez-Martínez F, López-López M, Santonja-Medina F. Patient-specific instrumentation in total knee arthroplasty. Expert Rev Med Devices 2019; 16 (07) 555-567
• 13 Hafez MA, Moholkar K. Patient-specific instruments: advantages and pitfalls. SICOT J 2017; 3: 66
• 14 Goldstein M, Feldmann C, Wulf H, Wiesmann T. Tranexamic acid prophylaxis in hip and knee joint replacement. Dtsch Arztebl Int 2017; 114 (48) 824-830
• 15 Melvin JS, Stryker LS, Sierra RJ. Tranexamic acid in hip and knee arthroplasty. J Am Acad Orthop Surg 2015; 23 (12) 732-740
• 16 Xiong H, Liu Y, Zeng Y, Wu Y, Shen B. The efficacy and safety of combined administration of intravenous and topical tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord 2018; 19 (01) 321
• 17 Xie J, Hu Q, Huang Q, Ma J, Lei Y, Pei F. Comparison of intravenous versus topical tranexamic acid in primary total hip and knee arthroplasty: an updated meta-analysis. Thromb Res 2017; 153: 28-36
• 18 Viegas R, Kumar A, Carvalho MM. et al. Impact of age, gender and body mass index on the efficacy of tranexamic acid in total knee arthroplasty. Int J Res Orthop 2020;
• 19 Guo P, He Z, Wang Y. et al. Efficacy and safety of oral tranexamic acid in total knee arthroplasty: a systematic review and meta-analysis. Medicine (Baltimore) 2018; 97 (18) e0587
• 20 Song SJ, Lee HW, Bae DK, Park CH. Daily blood loss transition after total knee arthroplasty with topical administration of tranexamic acid: Paradoxical blood loss after action of tranexamic acid. J Orthop Surg (Hong Kong) 2020; 28 (01) 2309499019895816
• 21 Volquind D, Zardo RA, Winkler BC, Londero BB, Zanelatto N, Leichtweis GP. Use of tranexamic acid in primary total knee replacement: effects on perioperative blood loss. Braz J Anesthesiol 2016; 66 (03) 254-258
• 22 Peng Zhang MM, Jifeng Li MM, Xiao Wang MM. Combined versus single application of tranexamic acid in total knee and hip arthroplasty: A meta-analysis of randomized controlled trials. Int J Surg 2017; 43: 171-180
• 23 Boyle JA, Soric MM. Impact of tranexamic acid in total knee and total hip replacement. J Pharm Pract 2017; 30 (01) 89-93
• 24 Fillingham YA, Ramkumar DB, Jevsevar DS. et al. The safety of tranexamic acid in total joint arthroplasty: a direct meta-analysis. J Arthroplasty 2018; 33 (10) 3070-3082
• 25 Yu X, Li W, Xu P, Liu J, Qiu Y, Zhu Y. Safety and efficacy of tranexamic acid in total knee arthroplasty. Med Sci Monit 2015; 21: 3095-3103
• 26 Kim Y-H, Park J-W, Kim J-S, Seo DH. Does tranexamic acid increase the risk of thromboembolism after bilateral simultaneous total knee arthroplasties in Asian Population?. Arch Orthop Trauma Surg 2018; 138 (01) 83-89
• 27 Hines JT, Hernandez NM, Amundson AW, Pagnano MW, Sierra RJ, Abdel MP. Intravenous tranexamic acid safely and effectively reduces transfusion rates in revision total hip arthroplasty. Bone Joint J 2019; 101-B (6_suppl _B): 104-109
• 28 Zhang LK, Ma JX, Kuang MJ. et al. The efficacy of tranexamic acid using oral administration in total knee arthroplasty: a systematic review and meta-analysis. J Orthop Surg Res 2017; 12 (01) 159
• 29 Sa-Ngasoongsong P, Wongsak S, Kulachote N, Chanplakorn P, Woratanarat P, Kawinwonggowit V. Predicting factors for allogeneic blood transfusion and excessive postoperative blood loss after single low-dosage intra-articular tranexamic acid application in total knee replacement. BioMed Res Int 2017; 2017: 2729487
• 30 Meng Y, Li Z, Gong K, An X, Dong J, Tang P. Tranexamic acid reduces intraoperative occult blood loss and tourniquet time in obese knee osteoarthritis patients undergoing total knee arthroplasty: a prospective cohort study. Ther Clin Risk Manag 2018; 14: 675-683
• 31 Burleson A, Guler N, Banos A. et al. Perioperative factors and their effect on the fibrinolytic system in arthroplasty patients. Clin Appl Thromb Hemost 2016; 22 (03) 274-279
• 32 Vilahur G, Ben-Aicha S, Badimon L. New insights into the role of adipose tissue in thrombosis. Cardiovasc Res 2017; 113 (09) 1046-1054
• 33 De Taeye BM, Novitskaya T, Gleaves L, Covington JW, Vaughan DE. Bone marrow plasminogen activator inhibitor-1 influences the development of obesity. J Biol Chem 2006; 281 (43) 32796-32805
• 34 Herrmann M. Marrow fat-secreted factors as biomarkers for osteoporosis. Curr Osteoporos Rep 2019; 17 (06) 429-437
• 35 Inaba Y, Yukizawa Y, Saito T. Coagulation and fibrinolysis markers and their use for the prediction of high risk patients with venous thromboembolism following total hip arthroplasty. Accessed May 21, 2021 at: https://www.intechopen.com/books/fibrinolysis-and-thrombolysis/coagulation-and-fibrinolysis-markers-and-their-use-for-the-prediction-of-high-risk-patients-with-ven
• 36 Yukizawa Y, Inaba Y, Watanabe S. et al. Association between venous thromboembolism and plasma levels of both soluble fibrin and plasminogen-activator inhibitor 1 in 170 patients undergoing total hip arthroplasty. Acta Orthop 2012; 83 (01) 14-21
• 37 Hunt BJ. Hemostasis at extremes of body weight. Semin Thromb Hemost 2018; 44 (07) 632-639
• 38 Suchacki KJ, Tavares AAS, Mattiucci D. et al. Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis. Nat Commun 2020; 11 (01) 3097
• 39 Cawthorn WP, Scheller EL. Editorial: bone marrow adipose tissue: formation, function, and impact on health and disease. Front Endocrinol (Lausanne) 2017; 8: 112
• 40 Li Y, Meng Y, Yu X. The unique metabolic characteristics of bone marrow adipose tissue. Front Endocrinol (Lausanne) 2019; 10: 69
• 41 Bastelica D, Morange P, Berthet B. et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002; 22 (01) 173-178
• 42 Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010; 28 (05) e72-e91